Mcm4 Antibody (D-4): sc-166193

Mcm4 Antibody (D-4) is a mouse monoclonal IgG2b antibody that detects Mcm4 in various species by applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Mcm4 is a crucial member of the mini-chromosome maintenance (MCM) protein family, which plays a vital role in the regulation of DNA replication, ensuring that DNA is replicated only once during each cell cycle. MCM proteins, including Mcm4, are essential for the formation of the pre-replicative complex and are activated during the transition from the G1 to S phase of the cell cycle. Mcm4, along with other MCM proteins, contains an ATP-binding motif that facilitates the ATP-dependent unwinding of double-stranded DNA, a critical step for the initiation of DNA replication. Additionally, Mcm4 interacts with various regulatory proteins, including E2F transcription factors, which enhance expression, and protein kinases that help maintain the post-replicative state of the cell. Notably, Mcm4 is part of a complex that exhibits DNA helicase activity, which is essential for unwinding DNA strands during replication. Anti-Mcm4 antibody (D-4) is an invaluable tool for researchers studying cell cycle regulation, DNA replication mechanisms, and the intricate interactions of MCM proteins in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Mcm4 Antibody (D-4) References:

1. Genetic screen for chromosome instability in mice: Mcm4 and breast cancer.  |  Shima, N., et al. 2007. Cell Cycle. 6: 1135-40. PMID: 17495541
2. G364R mutation of MCM4 detected in human skin cancer cells affects DNA helicase activity of MCM4/6/7 complex.  |  Ishimi, Y. and Irie, D. 2015. J Biochem. 157: 561-9. PMID: 25661590
3. An MCM4 mutation detected in cancer cells affects MCM4/6/7 complex formation.  |  Tatsumi, R. and Ishimi, Y. 2017. J Biochem. 161: 259-268. PMID: 27794528
4. E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.  |  Xie, L., et al. 2017. Eur Rev Med Pharmacol Sci. 21: 2150-2156. PMID: 28537669
5. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer.  |  Blanc, V., et al. 2021. J Clin Invest. 131: PMID: 33445170
6. Increased expression of MCM4 is associated with poor prognosis in patients with hepatocellular carcinoma.  |  Zheng, R., et al. 2021. J Gastrointest Oncol. 12: 153-173. PMID: 33708433
7. MCM4 in human hepatocellular carcinoma: a potent prognostic factor associated with cell proliferation.  |  Xu, Y., et al. 2021. Biosci Trends. 15: 100-106. PMID: 33716256
8. Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma.  |  Pei, LP., et al. 2022. Front Genet. 13: 890591. PMID: 35719366
9. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.  |  Yang, S., et al. 2022. Front Oncol. 12: 1004324. PMID: 36465369
10. MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.  |  Kobayashi, G., et al. 2023. Diagn Pathol. 18: 106. PMID: 37737200

The preferred MCM4 antibody is MCM4 Antibody (G-7): sc-28317.